Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:43:22 EDT Wed 01 May 2024
Enter Symbol
or Name
USA
CA



MONEY TALK RADIO with XORTX Therapeutics Inc. (XRTX) Dr. Allen Davidoff Explains Advanced Drug Therapy for Kidney Disease and Diabetes

2024-03-03 06:34 ET - News Release

Malibu, CA, United States, Mar 3, 2024 - (ABN Newswire) - This is Money Talk Radio with Ellis Martin. Today we're going to take a deep dive into a publicly traded NASDAQ company developing innovative therapies to improve the quality of life of patients with progressive kidney disease as well as diabetes. The company is XORTX Therapeutics Inc. (NASDAQ:XRTX)(CVE:XRTX) a late-stage clinical pharmaceutical company. We'll speak with Dr. Allen Davidoff. We urge you to pay attention to this dissertation, noting the revolutionary therapy being developed AND the potential investment opportunity therewithin.

XORTX Therapeutics is a paid sponsor of Money Talk Radio.

To Listen to the Interview, please visit:
https://www.abnnewswire.net/lnk/2HY6W9YL


About The Ellis Martin Report:

The Ellis Martin Report (TEMR) is an internet based radio program showcasing potentially undervalued companies to an audience of potential retail investors and fund managers that comprise our listening audience. TEMR is broadcasted on the VoiceAmerica Business Channel and The Opportunity Radio Network. CEO and company interviews are paid for by those represented on the program.

About XORTX Therapeutics, Inc.:

XORTX Therapeutics, Inc. (NASDAQ:XRTX) (CVE:XRTX) is a drug based biotechnology company primarily focused on orphan disease indications which have aberrant purine metabolism and frequently high serum uric acid imbalance. Our focus on developing kidney therapies also includes therapeutics programs for large markets such as diabetic nephropathy and acute kidney injury associated with respiratory virus infections such as SARS-CoV-2.

We possess patents and patent applications that may include U.S. and international rights regarding the development of uric acid-lowering agents for the treatment of hypertension, insulin resistance, diabetes, metabolic syndrome, and kidney injury.

Contact:
 
T: +1-403-455-7727
E: info@xortx.com
W: www.xortx.com


Source:
The Ellis Martin Report XORTX Therapeutics, Inc.

Copyright (C) 2024 ABN Newswire. All rights reserved.

© 2024 Canjex Publishing Ltd. All rights reserved.